The pharmaceutical supply chain tolerates no compromise. When a batch of temperature-sensitive biologics deviates by just a few degrees, or a vaccine shipment experiences delays within the broader supply chain, the consequences extend far beyond logistics metrics – they affect patient outcomes and public health.

Today’s pharmaceutical networks are increasingly complex, driven by global expansion, evolving healthcare purchasing models, tighter regulations, and the growing sensitivity and shorter life cycles of treatments such as oncology therapies and biologics. In this environment, the key question is no longer whether logistics partners can handle sensitive cargo, but whether they can do so consistently across a distributed global network.

The network effect in pharmaceutical logistics

Pharmaceutical supply chains no longer succeed or fail at individual locations. A vaccine manufacturer shipping through three continents needs assurance that handling standards in Algiers match those in Amsterdam or Atlanta. A single weak link – untrained teams, inadequate temperature monitoring, or non-standard processes – can compromise an entire shipment.

This reality demands a fundamental shift from evaluating isolated facility capabilities to assessing integrated network performance. Global air cargo operations must function as unified systems where harmonised processes and trained teams operate seamlessly across borders.

Swissport operates a global cargo network of 28 dedicated pharma centres and 63 pharma-capable warehouses, designed to reduce variability and ensure reliable handling performance of temperature-sensitive cargo across key trade lanes. For customers, this means lower risk, fewer product losses, and more reliable delivery to patients.

North Africa's growing role in healthcare distribution

North Africa is emerging as a strategically important corridor in pharmaceutical logistics, driven by rising healthcare demand and investment in cold-chain infrastructure. However, local capability alone is not enough – it must connect into global systems with consistent standards.

Algeria exemplifies this evolution. At Houari Boumediene Airport in Algiers, cargo operations support time- and temperature-sensitive pharmaceutical movements under globally aligned handling standards as part of integrated supply chains. The facility is IATA CEIV Pharma certified, confirming adherence to internationally recognized standards for quality management, team training, risk control, and temperature-sensitive handling.

This certification ensures pharmaceutical shipments moving through Algiers are handled according to the same operational principles applied across Swissport’s global pharma network.

Beyond certification, success depends on trained teams, specialised processes, and consistent operational execution across every stage of the shipment journey.

From certification to operational reality

Good Distribution Practices and regulations provide frameworks, but operational consistency delivers results. When pharmaceutical products move across regulatory jurisdictions, climates, and infrastructures, maintaining uniform handling standards is critical.

CEIV Pharma certification and Good Distribution Practice (GDP) requirements help align operational requirements across locations, from temperature control and team training to quality management systems. This reduces variability and strengthens predictability across international flows.

For customers, this translates into effective control of critical handling points at airports, helping maintain product integrity, reduce insurance costs, and improve on-time delivery performance. It also enables confident distribution planning in emerging markets where infrastructure is still developing but operational standards are already in place.

Supporting complex, multi-regional flows

Modern pharmaceutical distribution rarely involves simple point-to-point movements. Clinical trial shipments and temperature-sensitive therapies often move across multiple countries and handovers, requiring careful coordination across different regulatory environments and infrastructure conditions.

These complex flows require integrated cargo networks where locations function as connected nodes under aligned standards, processes and quality controls.

This approach gives pharmaceutical customers greater flexibility when entering new markets or diversifying supply chains. Instead of relying on fragmented logistics setups across regions, they can leverage integrated networks designed to maintain reliable performance across all locations.

The path forward

As pharmaceutical supply chains continue evolving, success increasingly depends on end-to-end network reliability rather than individual facility performance. The ability to maintain product integrity across multiple touchpoints and geographies is becoming the defining requirement of pharmaceutical logistics.

For regions like North Africa, integration into standardised global networks offers a dual opportunity: accelerating market access for manufacturers while strengthening healthcare resilience locally.

Through its network of dedicated pharma centres, pharma-capable warehouses and certified cargo operations, Swissport combines standards, infrastructure and operational expertise to support the safe and reliable movement of pharmaceutical products worldwide.

As pharmaceutical flows become increasingly complex and geographically distributed, the ability to combine local execution with global consistency will remain essential to ensuring life-saving medicines, vaccines and biologics reach the patients and communities that depend on them – safely, reliably and on time.